12 Month Price Forecast For IMCR
Distance to IMCR Price Forecasts
IMCR Price Momentum
๐ค Considering Immunocore (IMCR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 12, 2025 12:01 AM UTC
IMCR Analyst Ratings & Price Targets
Based on our analysis of 19 Wall Street analysts, IMCR has a bullish consensus with a median price target of $63.79 (ranging from $22.96 to $98.94). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $29.44, the median forecast implies a 116.7% upside. This outlook is supported by 12 Buy, 2 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMCR Analyst Consensus
IMCR Price Target Range
Latest IMCR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMCR.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Jan 10, 2025 | Needham | Buy | Reiterates | $0.00 | |
Dec 13, 2024 | Morgan Stanley | Andrew Galler | Equal-Weight | Downgrade | $35.00 |
Nov 11, 2024 | Mizuho | Graig Suvannavejh | Neutral | Downgrade | $38.00 |
Nov 7, 2024 | Needham | Gil Blum | Buy | Maintains | $71.00 |
Oct 24, 2024 | UBS | David Dai | Sell | Initiates | $24.00 |
Oct 24, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Oct 11, 2024 | Morgan Stanley | Andrew Galler | Overweight | Maintains | $74.00 |
Oct 7, 2024 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $0.00 |
Sep 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Sep 17, 2024 | Needham | Gil Blum | Buy | Maintains | $78.00 |
Sep 9, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
Aug 28, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Aug 9, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $89.00 |
Aug 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $81.00 |
Aug 9, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $66.00 |
Jul 10, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $66.00 |
Jun 5, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Jun 3, 2024 | Needham | Gil Blum | Buy | Reiterates | $81.00 |
May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $100.00 |
Stocks Similar to Immunocore Holdings plc
The following stocks are similar to Immunocore based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Immunocore Holdings plc (IMCR) Financial Data
Immunocore Holdings plc has a market capitalization of $1.47B with a P/E ratio of -25.0x. The company generates $296.31M in trailing twelve-month revenue with a -15.9% profit margin.
Revenue growth is +23.7% quarter-over-quarter, while maintaining an operating margin of -10.6% and return on equity of -12.8%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Immunocore Holdings plc (IMCR) Company Overview
About Immunocore Holdings plc
Develops immunotherapies for cancer and autoimmune diseases.
The company operates as a commercial-stage biotechnology firm, generating revenue primarily through the sale of its immunotherapy product KIMMTRAK, which targets specific cancer types. Additionally, Immunocore is advancing a robust pipeline of drug candidates in various stages of clinical trials, aiming to address multiple oncology and autoimmune disease indications, which could contribute to future revenue streams upon successful commercialization.
Founded in 1999 and headquartered in Abingdon, UK, Immunocore is focused on innovative treatments, including programs for advanced cutaneous melanoma and other cancers. The company is actively pursuing multiple clinical trials to expand its product offerings and enhance its market position in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
497
CEO
Dr. Bahija Jallal Ph.D.
Country
United Kingdom
IPO Year
2021
Website
www.immunocore.comImmunocore Holdings plc (IMCR) Latest News & Analysis
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade
29 days agoWall Street analysts project a potential upside of 113.1% for Immunocore (IMCR), supported by positive earnings estimate revisions.
A 113.1% upside in price targets for Immunocore suggests strong growth potential, while positive earnings revisions may further boost investor confidence and stock performance.
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
1 month agoKIMMTRAK (tebentafusp) aims to expand its reach to more mUM patients globally by 2025 through new launches and enhanced community penetration.
Expansion of KIMMTRAK indicates potential revenue growth for the company, enhancing market presence and possibly impacting stock performance positively.
Immunocore will present at the 43rd Annual J.P. Morgan Healthcare Conference, which may highlight its developments and future plans to investors.
Immunocore's presentation at a major healthcare conference could signal advancements in its pipeline, influencing stock performance and investor sentiment in biotech.
New Strong Buy Stocks for January 7th
1 month agoAORT, VERX, NN, IMCR, and EVER have been designated as Zacks Rank #1 (Strong Buy) as of January 7, 2024.
Zacks Rank #1 indicates strong growth potential for AORT, VERX, NN, IMCR, and EVER, suggesting favorable investment opportunities and potential price appreciation.
Immunocore has appointed Travis Coy as EVP, Chief Financial Officer, and Head of Corporate Development, previously serving as a Non-Executive Director.
Travis Coy's appointment as CFO and Head of Corporate Development may signal strategic shifts and financial stability, impacting investor confidence and potential stock performance.
Biotech stocks ALLO, DAWN, and IMCR faced declines in 2024 but are considered to have upside potential for 2025.
The mention of biotech stocks ALLO, DAWN, and IMCR suggests potential recovery opportunities, indicating possible value buys for investors looking for growth in 2025.
Frequently Asked Questions About IMCR Stock
What is Immunocore Holdings plc's (IMCR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, Immunocore Holdings plc (IMCR) has a median price target of $63.79. The highest price target is $98.94 and the lowest is $22.96.
Is IMCR stock a good investment in 2025?
According to current analyst ratings, IMCR has 12 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $29.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for IMCR stock?
Wall Street analysts predict IMCR stock could reach $63.79 in the next 12 months. This represents a 116.7% increase from the current price of $29.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immunocore Holdings plc's business model?
The company operates as a commercial-stage biotechnology firm, generating revenue primarily through the sale of its immunotherapy product KIMMTRAK, which targets specific cancer types. Additionally, Immunocore is advancing a robust pipeline of drug candidates in various stages of clinical trials, aiming to address multiple oncology and autoimmune disease indications, which could contribute to future revenue streams upon successful commercialization.
What is the highest forecasted price for IMCR Immunocore Holdings plc?
The highest price target for IMCR is $98.94 from at , which represents a 236.1% increase from the current price of $29.44.
What is the lowest forecasted price for IMCR Immunocore Holdings plc?
The lowest price target for IMCR is $22.96 from at , which represents a -22.0% decrease from the current price of $29.44.
What is the overall IMCR consensus from analysts for Immunocore Holdings plc?
The overall analyst consensus for IMCR is bullish. Out of 19 Wall Street analysts, 12 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $63.79.
How accurate are IMCR stock price projections?
Stock price projections, including those for Immunocore Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.